The article outlines a critical paradox in India’s pharmaceutical industry: while the nation has earned a global reputation as the "pharmacy of the world" by exporting affordable generic drugs and vaccines worldwide, its foundational reliance on Chinese raw materials leaves it highly vulnerable. As global markets transition toward a "China+1" strategy (diversifying supply chains away from China due to geopolitical and pandemic risks), India has a massive opportunity to lead, but it must first overcome deep structural dependencies.
Key Takeaways
The Sourcing Paradox: India exported $31.1 billion worth of pharma products in FY26. However, it imports an estimated 70–80% of its Active Pharmaceutical Ingredients (APIs) and chemical intermediates, with China being the dominant provider.
China’s Structural Edge: Over three decades, Chinese manufacturers built massive, fully integrated mega-plants with cheaper utilities and superior infrastructure. This allows them to underprice domestic Indian alternatives, making imports an economic necessity for Indian generic manufacturers who must maintain low costs.
The Global Window: Policy changes in regulated markets—such as the U.S. BIOSECURE Act and Europe’s Critical Medicines Act—are forcing global buyers to look for alternative, end-to-end supply chains outside of China.
Government Intervention: In response, India launched a ₹6,940 crore Production Linked Incentive (PLI) scheme for bulk drugs and is building dedicated bulk drug parks to revive the domestic production of 41 critical APIs and key starting materials (KSMs).
The Data at a Glance
The following table highlights the scale of India's international market reach alongside its internal reliance on imported chemical building blocks.
